ClinicalTrials.Veeva

Menu

VX-950 and Peginterferon for Hepatitis C

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

Status and phase

Completed
Phase 1

Conditions

Hepatitis C

Treatments

Drug: VX-950
Drug: peginterferon

Study type

Interventional

Funder types

Industry

Identifiers

NCT00251199
VX05-950-103

Details and patient eligibility

About

VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • infected with Hepatitis C virus

Exclusion criteria

  • contraindications to peginterferon therapy

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems